Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $230.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target lifted by Truist Financial from $220.00 to $230.00 in a research note released on Thursday,Benzinga reports. Truist Financial currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Needham & Company LLC restated a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $189.40.

Jazz Pharmaceuticals Stock Up 1.7 %

JAZZ stock opened at $138.81 on Thursday. The business has a 50 day moving average of $128.14 and a 200 day moving average of $120.03. The firm has a market cap of $8.43 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling

In related news, CMO Robert Iannone sold 7,080 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the transaction, the chief executive officer now owns 464,058 shares of the company’s stock, valued at approximately $66,940,366.50. The trade was a 1.38 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,193 shares of company stock worth $3,533,122. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bessemer Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 0.3% in the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock valued at $3,317,000 after buying an additional 92 shares in the last quarter. CIBC Asset Management Inc lifted its stake in Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after buying an additional 97 shares in the last quarter. Synovus Financial Corp grew its holdings in Jazz Pharmaceuticals by 0.5% during the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock valued at $2,365,000 after buying an additional 100 shares during the last quarter. Quarry LP increased its position in Jazz Pharmaceuticals by 6.3% during the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $209,000 after buying an additional 100 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.